# 利用深度学习，对免疫治疗中用于生存预测的纵向无创诊断进行多模态整合

发布时间：2024年11月27日

`LLM应用`

> Multimodal Integration of Longitudinal Noninvasive Diagnostics for Survival Prediction in Immunotherapy Using Deep Learning

# 摘要

> 目的：运用人工智能分析无创纵向及多模态数据，有望变革癌症患者的免疫疗法，为精准医疗开辟道路。方法：本研究整合了 694 名接受免疫治疗的泛癌患者队列在治疗前和治疗期间的血液检测数据、所开药物以及基于 CT 的器官体积等，以预测短期和长期总体生存率。借助近期的一系列进展，对基于扩展多模态转换器的简单时间注意力（MMTSimTA）网络的不同变体进行了端到端训练，用于预测 3、6、9 和 12 个月的死亡率。同时，将这些模型与采用基于中间和晚期融合集成方法的基线方法进行比较。结果：扩展的基于转换器的多模态模型预后性能最佳，其 3、6、9 和 12 个月生存预测的曲线下面积（AUCs）分别为 0.84 ± 0.04、0.83 ± 0.02、0.82 ± 0.02、0.81 ± 0.03。结论：我们的发现表明，分析综合的早期治疗数据对预测免疫治疗患者的生存率具有潜力。使用我们扩展的基于转换器的架构，将互补的无创模式整合到联合训练的模型中，展现出了更优的多模态预后性能，尤其在短期生存预测方面。

> Purpose: Analyzing noninvasive longitudinal and multimodal data using artificial intelligence could potentially transform immunotherapy for cancer patients, paving the way towards precision medicine. Methods: In this study, we integrated pre- and on-treatment blood measurements, prescribed medications and CT-based volumes of organs from a large pan-cancer cohort of 694 patients treated with immunotherapy to predict short and long-term overall survival. By leveraging a combination of recent developments, different variants of our extended multimodal transformer-based simple temporal attention (MMTSimTA) network were trained end-to-end to predict mortality at three, six, nine and twelve months. These models were also compared to baseline methods incorporating intermediate and late fusion based integration methods. Results: The strongest prognostic performance was demonstrated using the extended transformer-based multimodal model with area under the curves (AUCs) of $0.84 \pm $0.04, $0.83 \pm $0.02, $0.82 \pm $0.02, $0.81 \pm $0.03 for 3-, 6-, 9-, and 12-month survival prediction, respectively. Conclusion: Our findings suggest that analyzing integrated early treatment data has potential for predicting survival of immunotherapy patients. Integrating complementary noninvasive modalities into a jointly trained model, using our extended transformer-based architecture, demonstrated an improved multimodal prognostic performance, especially in short term survival prediction.

[Arxiv](https://arxiv.org/abs/2411.18253)